MedPath

Embark Early Education Ltd

Embark Early Education Ltd logo
🇩🇪Germany
Ownership
Public
Established
1993-01-01
Employees
5.1K
Market Cap
$1.3B
Website
http://evotec.com
Introduction

Evotec SE engages in the discovery and development of new drugs for pharmaceutical and biotechnology companies. It operates through the following segments: EVT Execute and EVT Innovate. The EVT Execute segment provides stand-alone or integrated drug discovery solutions for collaborators targets and programmers on a typical fee-for-service basis or through a variety of commercial structures, which may include performance-based components, such as milestones and royalties. The EVT Innovate develops drug discovery projects, assets and platforms, both internally or through academic collaborations. The company was founded by Manfred Eigen, Karsten Henco, Ulrich Aldag, Freimut Leidenberger, Heinrich Maria Schulte, Rudolf Rigler, and Charles Weissmann on December 8, 1993 and is headquartered in Hamburg, Germany.

biospace.com
·

QUANTRO Therapeutics reaches a milestone in the advancement of first-in-class cancer treatments

QUANTRO Therapeutics and Boehringer Ingelheim achieved a key R&D milestone, successfully applying QUANTROseq® technology to identify high-quality hits for an undruggable transcription factor, advancing first-in-class cancer treatments. QUANTRO will receive milestone payments, with potential transaction value exceeding EUR 500 million.
biospace.com
·

MitoRx Therapeutics Announces Scientific Advisory Board and Key Leadership Appointments

MitoRx Therapeutics appoints Christine Charman as Chief Development Officer, David Richardson as Finance Director, and four experts to its Scientific Advisory Board: Prof Chas Bountra, Prof Dame Kay Davies, Prof Laurent Servais, and Dr Bernd C Schwahn. These appointments aim to advance the company's mission to develop treatments for diseases caused by mitochondrial dysfunction.
nature.com
·

Tapping into the drug discovery potential of AI

Evotec and Exscientia used AI to develop an anticancer molecule in 8 months, a process traditionally taking 4-5 years. Exscientia's AI platform accelerates drug discovery, leading to partnerships and significant funding. AI's role in drug discovery is expanding, with companies like Recursion and BenevolentAI leveraging AI for innovative treatments and collaborations with pharma giants.
eqs-news.com
·

QUANTRO Therapeutics Launched with Breakthrough Oncology Drug

QUANTRO Therapeutics GmbH, launched with seed financing from Boehringer Ingelheim Venture Fund and Evotec, aims to revolutionize drug discovery in oncology through its 'Transcriptional Fingerprinting' technology. This innovative approach targets oncogenic transcription factors, previously challenging to address, to develop novel therapeutics for cancer and other diseases.
finance.yahoo.com
·

Evotec Enters Partnership with Quantro Therapeutics

Evotec SE partners with QUANTRO Therapeutics to develop novel therapeutics targeting 'undruggable' cancer transcription factors using innovative functional-genetic and transcriptomic technologies. Evotec and Boehringer Ingelheim Venture Fund invest in QUANTRO, aiming to revolutionize drug discovery with time-resolved RNA sequencing.
© Copyright 2025. All Rights Reserved by MedPath